Monthly Prescribing Reference

FDA Approves New Dosage Strengths of Austedo XR

Austedo XR is now available in 30mg, 36mg, 42mg, and 48mg tablet strengths. The Food and Drug Administration (FDA) has approved new dosage strengths for Austedo ® XR (deutetrabenazine extended-release ...
Nasdaq

Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® (deutetrabenazine) tablets The U.S. Food and Drug Administration ...
Monthly Prescribing Reference

Austedo Xr

Deutetrabenazine 6mg, 12mg, 18mg, 24mg, 30mg, 36mg, 42mg, 48mg; ext-rel tabs. Swallow whole. Take with or without food. Individualize. Initially 12mg once daily; may titrate at weekly intervals by 6mg ...
Healthline

Austedo vs. Ingrezza: Uses, Side Effects, and More

Austedo (deutetrabenazine) and Ingrezza (valbenazine) are prescription drugs used to treat tardive dyskinesia and chorea associated with Huntington’s disease. Austedo and Ingrezza are not available as ...
Nasdaq

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the ...